Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates : Episode 1
Opinion
Video
Treatment Strategies for NSCLC with Non-Actionable Mutations
Author(s):
Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD; and Benjamin Levy, MD, provide a concise overview of current first-line treatment options for non-small cell lung cancer (NSCLC), including their approaches for NSCLC with non-actionable mutations and the influence of PD-L1 tumor proportion score status on treatment choices.
- Please provide a brief overview of the landscape surrounding first-line treatment of NSCLC.
- What treatment options are available?
- How do treatment approaches differ between patients with actionable vs non-actionable mutations?
- Briefly outline your general treatment approach for NSCLC with non-actionable mutations. (Singh, et al. J Clin Oncol, 2022)
- What is the role of immunotherapy (IO) in this treatment space?
- What factors are most critical for guiding treatment selection?
- How may your treatment approach differ based on PD-L1 TPS status?
Latest CME
View All
Video
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Jun 6th 2025 - Jul 12th 2025
online-activity
Video
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Jun 6th 2025 - Jul 12th 2025
online-activity
Video
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Jun 5th 2025 - Jul 12th 2025
online-activity
Related Content
